AI Article Synopsis
- The study aimed to evaluate the effectiveness and results of administering darbepoetin-alpha (an anemia treatment) at extended intervals, such as once a month, in a large group of dialysis patients.
- The research involved 175 adult patients from 23 Swiss hemodialysis centers who switched from their previous treatments to extended dosing intervals of darbepoetin-alpha, with their hemoglobin levels monitored over time.
- Findings revealed that after an average of 9.5 months, many patients successfully transitioned to less frequent dosing without significant changes in hemoglobin levels, indicating the approach was well-received.
Article Abstract
Aim: To document the feasibility and report the results of dosing darbepoetin-alpha at extended intervals up to once monthly (QM) in a large dialysis patient population.
Material: 175 adult patients treated, at 23 Swiss hemodialysis centres, with stable doses of any erythropoiesis-stimulating agent who were switched by their physicians to darbepoetin-alpha treatment at prolonged dosing intervals (every 2 weeks [Q2W] or QM).
Method: Multicentre, prospective, observational study. Patients' hemoglobin (Hb) levels and other data were recorded 1 month before conversion (baseline) to an extended darbepoetin-alpha dosing interval, at the time of conversion, and once monthly thereafter up to the evaluation point (maximum of 12 months or until loss to follow-up).
Results: Data for 161 evaluable patients from 23 sites were included in the final analysis. At 1 month prior to conversion, 73% of these patients were receiving darbepoetin-alpha weekly (QW) and 27% of the patients biweekly (Q2W). After a mean follow-up of 9.5 months, 34% received a monthly (QM) dosing regimen, 52% of the patients were receiving darbepoetin-alpha Q2W, and 14% QW. The mean (SD) Hb concentration at baseline was 12.3 +/- 1.2 g/dl, compared to 11.9 +/- 1.2 g/dl at the evaluation point. The corresponding mean weekly darbepoetin-alpha dose was 44.3 +/- 33.4 microg at baseline and 37.7 +/- 30.8 microg at the evaluation point.
Conclusions: Conversion to extended darbepoetin-alpha dosing intervals of up to QM, with maintenance of initial Hb concentrations, was successful for the majority of stable dialysis patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/cnp71697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Darbepoetin alpha has an anxiolytic and anti-neuroinflammatory effect in male rats.
BMC Immunol
November 2024
Physiology Department, Ankara University Medicine Faculty, Ankara, Turkey.
Aims: We aimed to investigate the anxiolytic effect of darbepoetin alpha (DEPO), an erythropoietin derivative, in a neuroinflammation model regarding different behaviors and biological pathways.
Methods: Forty adult male Wistar albino rats were divided into four groups (control, LPS, DEPO, and DEPO + LPS). The rats were treated with 5 µg /kg DEPO once a week for four weeks, after which neuroinflammation was induced with 2 mg/kg lipopolysaccharide (LPS).
Drug-induced hyperglycemia and diabetes.
Therapie
April 2024
CHU de Montpellier, Medical Pharmacology and Toxicology Department, 34000 Montpellier, France; IDESP, Université de Montpellier, Inserm, 34295 Montpellier, France. Electronic address:
Background: Drug-induced hyperglycemia and diabetes have negative and potentially serious health consequences but can often be unnoticed.
Methods: We reviewed the literature searching Medline database for articles addressing drug-induced hyperglycemia and diabetes up to January 31, 2023. We also selected drugs that could induce hyperglycemia or diabetes according official data from drug information databases Thériaque and Micromedex.
Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With NonDialysis-Dependent CKD: A Post Hoc Regional Analysis of the PROTECT Randomized Clinical Trial of ESA-Treated Patients.
Kidney Med
July 2023
Section of Nephrology, Baylor College of Medicine, Houston, TX.
Article Synopsis
- In the PROTECT trials, a new drug called vadadustat was compared to a drug named darbepoetin alfa for treating patients with kidney disease and anemia.
- They found that while vadadustat worked similarly for improving blood health, it had more risks for serious heart problems in certain regions, especially in Europe.
- Overall, patients in Europe experienced a higher rate of heart problems compared to those in the US and other regions, suggesting location may affect treatment outcomes.
Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis.
Lab Invest
February 2023
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:
Exogenous erythropoietin (EPO) is used to treat anemia in patients with chronic kidney disease (CKD). Concerns about the possible adverse effect of EPO on the progression of CKD have been raised owing to nonerythroid cell effects. We investigated the effects of low-dose EPO, independent of correcting anemia, on existing glomerulosclerosis.
View Article and Find Full Text PDFErythropoietin promotes myocardial infarction repair in mice by improving the function of Sca-1 stem cells.
Sheng Li Xue Bao
February 2023
Key Laboratory of Cellular Physiology, Ministry of Education, and the Department of Physiology, School of Basic Sciences, Shanxi Medical University, Taiyuan 030001, China.
Myocardial infarction (MI) is one of the leading causes of death in the world. With the improvement of clinical therapy, the mortality of acute MI has been significantly reduced. However, as for the long-term impact of MI on cardiac remodeling and cardiac function, there is no effective prevention and treatment measures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!